01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Venture Life Group #VLG – CEO Jerry Randall discusses today’s interim results & trading update September 24, 2020 – Posted in: Venture Life Group (VLG)

Alan Green talks to Venture Life Group (VLG) CEO Jerry Randall about the company’s interim results. Jerry goes through the numbers and commercial developments for the period, before discussing post period-end developments, including an independent study at Cardiff University on the effects on Dentyl Dual Action mouthwash on patients affected by COVID-19. Jerry explains the resilience and adaptability of the Venture Life business model in countering the challenge of the COVID lockdown, and highlights how…

Continue reading

Venture Life Group VLG – Trading Update July 20th 2020 July 20, 2020 – Posted in: Venture Life Group (VLG)

Alan Green talks to Venture Life Group (VLG) CEO Jerry Randall about today’s trading update. Jerry provides an overview of the VLG offering, and then discusses the financial and commercial highlights in today’s statement. Looking forward Jerry covers VLG’s strong financial position, and how non-dilutive funding will be used for further acquisitions, some of which (subject to Covid restrictions), may arrive before Christmas 2020. Jerry also provides key points for investors going forward. 1) Earnings…

Continue reading

Venture Life Group (AIM: VLG) – Alan Green talks to CEO Jerry Randall June 9, 2020 – Posted in: Venture Life Group (VLG)

Alan Green talks Jerry Randall, CEO of Venture Life Group (AIM: VLG). Jerry provides an overview of the company operating structure and strategy, and then covers today’s trading statement, going into detail on the very strong trading that will see the company ‘comfortably exceed market expectations’ for the year. Jerry covers the group’s commercial relationships and partners, provides detail on the strong funding position and provides an outlook for value inflection points going forward.

Continue reading

Keeping pace with Open Orphan February 3, 2020 – Posted in: Open Orphan (ORPH)

It’s been an exceptionally busy few months for Open Orphan (ORPH) and its Executive Chairman Cathal Friel. Since reversing into Venn Life Sciences last summer, Open Orphan has set it’s sights on a series of acquisitions to forge a specialist pharmaceutical services group with a focus on orphan drugs. In raising the money to complete the Venn Life Sciences and recent hVIVO acquisitions,  Friel has invested over £2m of his own money through his investment…

Continue reading